Molecular targeting to treat gastric cancer

Area of Science:

• Oncology
• Gastroenterology
• Molecular Biology

Background:

• Trastuzumab, targeting human epidermal growth factor receptor 2 (HER2), is the sole approved molecularly targeted therapy for gastric cancer in Japan, demonstrating favorable outcomes.
• Despite its approval, Trastuzumab's efficacy is restricted to 10-20% of HER2-expressing gastric cancer patients.
• Targeted therapies like bevacizumab (anti-vascular endothelial growth factor) and EGFR inhibitors (cetuximab, panitumumab) have shown limited success in gastric cancer.

Purpose of the Study:

• To evaluate the current landscape and future directions of molecularly targeted therapy for gastric cancer.
• To assess the potential of ramucirumab as a targeted treatment option for gastric cancer.
• To underscore the need for further research and clinical trials in molecularly targeted therapy for gastric cancer.

Main Methods:

• Review of existing clinical trial data and approved therapies for gastric cancer.
• Analysis of the efficacy of Trastuzumab in HER2-positive gastric cancer.
• Examination of the outcomes of targeted therapies including bevacizumab, cetuximab, panitumumab, and ramucirumab in gastric cancer.

Main Results:

• Trastuzumab is effective in a small subset of HER2-positive gastric cancer patients.
• Bevacizumab, cetuximab, and panitumumab have not proven effective for gastric cancer treatment.
• Ramucirumab, targeting VEGF receptor-2, demonstrated prolonged overall survival in a Phase III trial, suggesting potential efficacy.

Conclusions:

• The role of molecularly targeted therapy in gastric cancer remains a subject of debate.
• Ramucirumab represents a promising molecularly targeted therapy for gastric cancer.
• There is a critical need for large-scale randomized clinical trials investigating novel molecularly targeted agents for gastric cancer treatment.